INHIBITION BY 2 LAVENDUSTINS OF THE TYROSINE KINASE-ACTIVITY OF PP60(F527) IN-VITRO AND IN INTACT-CELLS

被引:16
作者
AGBOTOUNOU, WK
UMEZAWA, K
JACQUEMINSABLON, A
PIERRE, J
机构
[1] INST GUSTAVE ROUSSY,CNRS,URA 147,F-94805 VILLEJUIF,FRANCE
[2] KEIO UNIV,FAC SCI & TECHNOL,DEPT APPL CHEM,KOHOKU KU,YOKOHAMA,KANAGAWA 223,JAPAN
来源
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION | 1994年 / 269卷 / 01期
关键词
PP60(F527); TYROSINE PHOSPHORYLATION; LAVENDUSTIN A AND C6; TYROSINE KINASE INHIBITORS;
D O I
10.1016/0922-4106(94)90019-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The mutant pp60(F527) protein possesses an activate protein-tyrosine kinase (PTK) activity correlated with a transforming activity. We have studied the inhibition of the pp60(F527) PTK activity by two EGF-R tyrosine kinase inhibitors, lavendustin A and one of its derivatives, lavendustin C6. In vitro, both molecules were non-competitive inhibitors for the ATP binding site and uncompetitive inhibitors for the peptide binding site. The determined IC(50)s of the inhibition of pp60(F527) kinase activity were 18 mu M for lavendustin A and 5 mu M for lavendustin C6, as determined on the exogenous substrate enolase, showing that lavendustin C6 was more potent than lavendustin A. Lavendustin C6, but not lavendustin A, inhibited the tyrosine phosphorylation of pp60(F527) cellular substrates (the GAP-associated p190, pp125(FAK) and cortactin) in intact cells. However, this in situ inhibitory effect did not result in a reversion of the morphological changes induced by pp60(F527) in cells. On the other hand, lavendustin C6 and lavendustin A exerted antiproliferative effects on cells, suggesting that inhibition of cellular targets related or not to the kinase was also possible.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 37 条
  • [1] ABLER A, 1992, J BIOL CHEM, V267, P3946
  • [2] AGBOTOUNOU KW, 1994, MOL PHARMACOL, V45, P922
  • [3] AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
  • [4] BARNEKOW A, 1987, CANCER RES, V47, P235
  • [5] THE HUMAN P50(CSK) TYROSINE KINASE PHOSPHORYLATES P56(LCK) AT TYR-505 AND DOWN REGULATES ITS CATALYTIC ACTIVITY
    BERGMAN, M
    MUSTELIN, T
    OETKEN, C
    PARTANEN, J
    FLINT, NA
    AMREIN, KE
    AUTERO, M
    BURN, P
    ALITALO, K
    [J]. EMBO JOURNAL, 1992, 11 (08) : 2919 - 2924
  • [6] ACTIVATION OF PP60C-SRC PROTEIN-KINASE ACTIVITY IN HUMAN-COLON CARCINOMA
    BOLEN, JB
    VEILLETTE, A
    SCHWARTZ, AM
    DESEAU, V
    ROSEN, N
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (08) : 2251 - 2255
  • [7] BURKE T R JR, 1992, Drugs of the Future, V17, P119
  • [8] PP60C-SRC ACTIVATION IN HUMAN-COLON CARCINOMA
    CARTWRIGHT, CA
    KAMPS, MP
    MEISLER, AI
    PIPAS, JM
    ECKHART, W
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (06) : 2025 - 2033
  • [9] TYR527 IS PHOSPHORYLATED IN PP60C-SRC - IMPLICATIONS FOR REGULATION
    COOPER, JA
    GOULD, KL
    CARTWRIGHT, CA
    HUNTER, T
    [J]. SCIENCE, 1986, 231 (4744) : 1431 - 1434
  • [10] DEPHOSPHORYLATION OR ANTIBODY-BINDING TO THE CARBOXY TERMINUS STIMULATES PP60C-SRC
    COOPER, JA
    KING, CS
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1986, 6 (12) : 4467 - 4477